Modality
Vaccine
MOA
DLL3 ADC
Target
PD-1
Pathway
RNA Splicing
Alzheimer's
Development Pipeline
Preclinical
~Dec 2018
→ ~Mar 2020
Phase 1
~Jun 2020
→ ~Sep 2021
Phase 2
Dec 2021
→ Aug 2025
Phase 2Current
NCT04254379
238 pts·Alzheimer's
2022-10→2025-08·Terminated
NCT04998295
2,093 pts·Alzheimer's
2021-12→2025-06·Terminated
2,331 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-06-259mo agoPh3 Readout· Alzheimer's
2025-08-237mo agoPh3 Readout· Alzheimer's
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3
P2/3
Termina…
P2/3
Termina…
Catalysts
Ph3 Readout
2025-06-25 · 9mo ago
Alzheimer's
Ph3 Readout
2025-08-23 · 7mo ago
Alzheimer's
Terminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04254379 | Phase 2/3 | Alzheimer's | Terminated | 238 | PANSS |
| NCT04998295 | Phase 2/3 | Alzheimer's | Terminated | 2093 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| Rimamavacamten | Merck & Co | Phase 1 | PI3Kα | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| MRN-8133 | Moderna | Phase 2 | PD-1 | |
| Semazasiran | BeiGene | Phase 1 | PD-1 | |
| Rimainavolisib | Illumina | Phase 2 | PD-1 | |
| Motanaritide | Intellia | Approved | PD-1 | |
| Tixatapinarof | Arvinas | Phase 1/2 | CDK2 |